Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful hard but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last few shares of mine. My 1st CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire job interview which I came away with a bad opinion of the company.

Irony of irony, my bad opinion of the business has grown steadily, however, the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this know-how and also connected intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and also the very first new drug program endorsement ($5 million), as well as royalty payments of 5 % of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple therapies and multiple indications, it has this individual treatment as well as a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple delivering presentations and multiple publications.

Could all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this business. Judging with the multiples of a huge number of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *